Patient- and transplant-related characteristics
| Variable . | Overall (n = 259) . | BM (n = 126) . | PB (n = 133) . | P . |
|---|---|---|---|---|
| Sex | 0.31 | |||
| Male | 152 (59) | 78 (62) | 74 (56) | |
| Female | 107 (41) | 48 (38) | 59 (44) | |
| Age at transplantation, y | 0.90 | |||
| Median (range) | 44 (0.4-67) | 42 (5-67) | 41 (0.4-67) | |
| Race | 0.20 | |||
| Nonwhite | 20 (8) | 7 (6) | 13 (10) | |
| White | 239 (92) | 119 (94) | 120 (90) | |
| CMV group | 0.11 | |||
| CMVr | 34 (13) | 22 (18) | 12 (9) | |
| CMV+ | 110 (43) | 53 (42) | 57 (43) | |
| CMV− | 115 (44) | 51 (41) | 64 (48) | |
| Disease group | 0.43 | |||
| Acute myeloid leukemia | 127 (49) | 59 (47) | 68 (51) | |
| Acute lymphoblastic leukemia | 59 (23) | 30 (24) | 29 (22) | |
| Chronic myeloid leukemia | 25 (10) | 13 (10) | 12 (9) | |
| Myelodysplastic syndrome | 40 (15) | 22 (18) | 18 (14) | |
| Chronic myelomonocytic leukemia | 4 (2) | 2 (2) | 2 (2) | |
| Myelofibrosis | 4 (2) | 0 (0) | 4 (3%) | |
| HLA match degree | 0.07 | |||
| 5/6 | 26 (10) | 17 (14) | 9 (7) | |
| 6/6 | 233 (90) | 109 (87) | 124 (93) | |
| Acute GVHD grade II to IV by day 100 | 0.52 | |||
| No | 143 (55) | 67 (53) | 76 (57) | |
| Yes | 116 (45) | 59 (47) | 57 (43) |
| Variable . | Overall (n = 259) . | BM (n = 126) . | PB (n = 133) . | P . |
|---|---|---|---|---|
| Sex | 0.31 | |||
| Male | 152 (59) | 78 (62) | 74 (56) | |
| Female | 107 (41) | 48 (38) | 59 (44) | |
| Age at transplantation, y | 0.90 | |||
| Median (range) | 44 (0.4-67) | 42 (5-67) | 41 (0.4-67) | |
| Race | 0.20 | |||
| Nonwhite | 20 (8) | 7 (6) | 13 (10) | |
| White | 239 (92) | 119 (94) | 120 (90) | |
| CMV group | 0.11 | |||
| CMVr | 34 (13) | 22 (18) | 12 (9) | |
| CMV+ | 110 (43) | 53 (42) | 57 (43) | |
| CMV− | 115 (44) | 51 (41) | 64 (48) | |
| Disease group | 0.43 | |||
| Acute myeloid leukemia | 127 (49) | 59 (47) | 68 (51) | |
| Acute lymphoblastic leukemia | 59 (23) | 30 (24) | 29 (22) | |
| Chronic myeloid leukemia | 25 (10) | 13 (10) | 12 (9) | |
| Myelodysplastic syndrome | 40 (15) | 22 (18) | 18 (14) | |
| Chronic myelomonocytic leukemia | 4 (2) | 2 (2) | 2 (2) | |
| Myelofibrosis | 4 (2) | 0 (0) | 4 (3%) | |
| HLA match degree | 0.07 | |||
| 5/6 | 26 (10) | 17 (14) | 9 (7) | |
| 6/6 | 233 (90) | 109 (87) | 124 (93) | |
| Acute GVHD grade II to IV by day 100 | 0.52 | |||
| No | 143 (55) | 67 (53) | 76 (57) | |
| Yes | 116 (45) | 59 (47) | 57 (43) |
Data are presented as n (%), unless otherwise indicated.
CMVr, patients who reactivated CMV by day 100; CMV+, CMV-seropositive patients who did not reactivate CMV by day 100; CMV−, CMV-seronegative patients who did not reactivate CMV.